Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label multicenter study of HL-085 plus vemurafenib in BRAF V600-mutant metastatic colorectal cancer
CTR20213322Phase 2Active
- Sponsor
- Shanghai KeChow Pharmaceuticals
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tunlametinib, vemurafenib in colorectal cancer (CRC), sponsored by Shanghai KeChow Pharmaceuticals. Started Mar 2022; status: active.
02
Drugs
tunlametinibvemurafenib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on CTR20213322.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20213322.